CPT code 87900 denotes a laboratory test that predicts a virus’s susceptibility or resistance to antiviral medications by comparing patient-derived data with updated genotypic bioinformatics to infer phenotype. This molecular/virology diagnostic supports clinicians in selecting appropriate antiviral therapy and can influence treatment effectiveness, antimicrobial stewardship, and downstream healthcare utilization nationally.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for genotypic-to-phenotypic antiviral testing, typical settings where this service is performed (clinical and hospital laboratories), and what payers commonly consider when determining coverage. The publication summarizes benchmarks and payer policy themes relevant to molecular virology testing, highlights common billing considerations, and notes areas where coding clarity or policy updates may affect claims processing.

This executive summary is intended for a national audience of clinicians, laboratory managers, and revenue cycle professionals seeking concise information on the clinical purpose of CPT code 87900, the primary payers involved, and the types of operational and policy topics that affect use and reimbursement.